255 related articles for article (PubMed ID: 33436648)
1. Integrative microRNA and gene expression analysis identifies new epigenetically regulated microRNAs mediating taxane resistance in ovarian cancer.
Hassan MK; Waly AA; Elsayed W; Keshk S; Allam WR; El-Khamisy SF
Sci Rep; 2021 Jan; 11(1):562. PubMed ID: 33436648
[TBL] [Abstract][Full Text] [Related]
2. MiR-181c sensitizes ovarian cancer cells to paclitaxel by targeting GRP78 through the PI3K/Akt pathway.
Zhang LY; Yu JY; Leng YL; Zhu RR; Liu HX; Wang XY; Yang TT; Guo YN; Tang JL; Zhang XC
Cancer Gene Ther; 2022 Jun; 29(6):770-783. PubMed ID: 34145425
[TBL] [Abstract][Full Text] [Related]
3. Roles of a TMPO-AS1/microRNA-200c/TMEFF2 ceRNA network in the malignant behaviors and 5-FU resistance of ovarian cancer cells.
Li H; Zhou Y; Cheng H; Tian J; Yang S
Exp Mol Pathol; 2020 Aug; 115():104481. PubMed ID: 32497621
[TBL] [Abstract][Full Text] [Related]
4. MiRNA-mRNA integrative analysis reveals epigenetically regulated and prognostic miR-103a with a role in migration and invasion of carboplatin-resistant ovarian cancer cells that acquired mesenchymal-like phenotype.
Pernar Kovač M; Tadić V; Kralj J; Milković Periša M; Orešković S; Babić I; Banović V; Zhang W; Culig Z; Brozovic A
Biomed Pharmacother; 2023 Oct; 166():115349. PubMed ID: 37634476
[TBL] [Abstract][Full Text] [Related]
5. miR-130a activates apoptotic signaling through activation of caspase-8 in taxane-resistant prostate cancer cells.
Fujita Y; Kojima T; Kawakami K; Mizutani K; Kato T; Deguchi T; Ito M
Prostate; 2015 Oct; 75(14):1568-78. PubMed ID: 26074357
[TBL] [Abstract][Full Text] [Related]
6. The miR-33a-5p/CROT axis mediates ovarian cancer cell behaviors and chemoresistance
Li X; Gao X; Yuan J; Wang F; Xu X; Wang C; Liu H; Guan W; Zhang J; Xu G
Front Endocrinol (Lausanne); 2022; 13():950345. PubMed ID: 36120434
[TBL] [Abstract][Full Text] [Related]
7. Smoothened antagonists reverse taxane resistance in ovarian cancer.
Steg AD; Katre AA; Bevis KS; Ziebarth A; Dobbin ZC; Shah MM; Alvarez RD; Landen CN
Mol Cancer Ther; 2012 Jul; 11(7):1587-97. PubMed ID: 22553355
[TBL] [Abstract][Full Text] [Related]
8. Transcriptomic analysis reveals tumor stage- or grade-dependent expression of miRNAs in serous ovarian cancer.
Berkel C; Cacan E
Hum Cell; 2021 May; 34(3):862-877. PubMed ID: 33576947
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic strategies to overcome taxane resistance in cancer.
Das T; Anand U; Pandey SK; Ashby CR; Assaraf YG; Chen ZS; Dey A
Drug Resist Updat; 2021 Mar; 55():100754. PubMed ID: 33691261
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
11. miRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation.
Wuerkenbieke D; Wang J; Li Y; Ma C
Arch Gynecol Obstet; 2015 Nov; 292(5):1109-16. PubMed ID: 25986891
[TBL] [Abstract][Full Text] [Related]
12. Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer.
Chen Y; Cao XY; Li YN; Qiu YY; Li YN; Li W; Wang H
Am J Physiol Cell Physiol; 2018 Aug; 315(2):C225-C235. PubMed ID: 29719173
[TBL] [Abstract][Full Text] [Related]
13. Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer.
Chen X; Wang YW; Xing AY; Xiang S; Shi DB; Liu L; Li YX; Gao P
J Pathol; 2016 Aug; 239(4):459-72. PubMed ID: 27171498
[TBL] [Abstract][Full Text] [Related]
14. CircATL2 enhances paclitaxel resistance of ovarian cancer via impacting miR-506-3p/NFIB axis.
Ying H; Zhao R; Yu Q; Zhang K; Deng Q
Drug Dev Res; 2022 Apr; 83(2):512-524. PubMed ID: 34541682
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
Wu D; Lu P; Mi X; Miao J
Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
[TBL] [Abstract][Full Text] [Related]
16. UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis.
Wang J; Ye C; Liu J; Hu Y
Biochem Biophys Res Commun; 2018 Jul; 501(4):1034-1040. PubMed ID: 29777711
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.
Li ZY; Wang XL; Dang Y; Zhu XZ; Zhang YH; Cai BX; Zheng L
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):591-603. PubMed ID: 32016960
[TBL] [Abstract][Full Text] [Related]
18. Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.
Singh S; Chitkara D; Mehrazin R; Behrman SW; Wake RW; Mahato RI
PLoS One; 2012; 7(6):e40021. PubMed ID: 22768203
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview.
Saburi A; Kahrizi MS; Naghsh N; Etemadi H; İlhan A; Adili A; Ghoreishizadeh S; Tamjidifar R; Akbari M; Ercan G
J Ovarian Res; 2022 Jul; 15(1):81. PubMed ID: 35799305
[TBL] [Abstract][Full Text] [Related]
20. A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells.
Liu W; Wang S; Zhou S; Yang F; Jiang W; Zhang Q; Wang L
Mol Biosyst; 2017 Oct; 13(11):2268-2276. PubMed ID: 28861582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
